Koh Furugaki

963 total citations
20 papers, 645 citations indexed

About

Koh Furugaki is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Koh Furugaki has authored 20 papers receiving a total of 645 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Koh Furugaki's work include Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (4 papers) and Lung Cancer Research Studies (4 papers). Koh Furugaki is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (4 papers) and Lung Cancer Research Studies (4 papers). Koh Furugaki collaborates with scholars based in United States and Japan. Koh Furugaki's co-authors include Keigo Yorozu, Mitsue Kurasawa, Kaori Fujimoto-Ouchi, Yoriko Yamashita‐Kashima, Mieko Yanagisawa, Toshiki Iwai, Shigeyuki Iijima, Masateru Ohta, Yoichiro Moriya and Naoki Harada and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

Koh Furugaki

20 papers receiving 614 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Koh Furugaki United States 12 407 281 274 142 74 20 645
Kaori Fujimoto-Ouchi United States 15 552 1.4× 283 1.0× 242 0.9× 241 1.7× 54 0.7× 28 823
Hoa Q. Trummell United States 13 360 0.9× 176 0.6× 305 1.1× 71 0.5× 82 1.1× 19 620
A. Lambiase Italy 17 613 1.5× 181 0.6× 297 1.1× 146 1.0× 102 1.4× 55 899
Marissa S. Mattar United States 12 313 0.8× 230 0.8× 290 1.1× 42 0.3× 153 2.1× 22 666
Muyun Peng China 11 333 0.8× 270 1.0× 217 0.8× 78 0.5× 145 2.0× 34 710
Kristin Gurtner Germany 11 266 0.7× 188 0.7× 256 0.9× 91 0.6× 38 0.5× 16 595
S. Ménard Canada 7 243 0.6× 285 1.0× 368 1.3× 104 0.7× 30 0.4× 10 697
H.A. Burris United States 13 496 1.2× 213 0.8× 316 1.2× 111 0.8× 20 0.3× 63 679
Songbing Qin China 14 440 1.1× 206 0.7× 179 0.7× 164 1.2× 239 3.2× 54 789
Katharine D. Grugan United States 9 301 0.7× 84 0.3× 286 1.0× 109 0.8× 159 2.1× 12 585

Countries citing papers authored by Koh Furugaki

Since Specialization
Citations

This map shows the geographic impact of Koh Furugaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Koh Furugaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Koh Furugaki more than expected).

Fields of papers citing papers by Koh Furugaki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Koh Furugaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Koh Furugaki. The network helps show where Koh Furugaki may publish in the future.

Co-authorship network of co-authors of Koh Furugaki

This figure shows the co-authorship network connecting the top 25 collaborators of Koh Furugaki. A scholar is included among the top collaborators of Koh Furugaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Koh Furugaki. Koh Furugaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Furugaki, Koh, Yasutaka Watanabe, Ken Uchibori, et al.. (2024). Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK‐inhibitor‐induced tolerant persister cells in ALK‐fusion‐positive lung cancer. Molecular Oncology. 19(2). 519–539. 4 indexed citations
2.
Furugaki, Koh, Satoshi Muraoka, Makoto Nishio, et al.. (2024). Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer. npj Precision Oncology. 8(1). 264–264. 4 indexed citations
3.
Furugaki, Koh, et al.. (2023). FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes. npj Precision Oncology. 7(1). 107–107. 13 indexed citations
4.
Funazo, Tomoko, Takahiro Tsuji, Hiroaki Ozasa, et al.. (2020). Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model. Molecular Cancer Therapeutics. 19(6). 1320–1327. 5 indexed citations
5.
Tsuji, Takahiro, Hiroaki Ozasa, Wataru Aoki, et al.. (2020). YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation. Nature Communications. 11(1). 74–74. 57 indexed citations
6.
7.
Furugaki, Koh, et al.. (2019). Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion. BMC Cancer. 19(1). 301–301. 11 indexed citations
8.
Yamashita‐Kashima, Yoriko, Yasushi Yoshimura, Mieko Yanagisawa, et al.. (2019). Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody–cytotoxic drug conjugate. Cancer Chemotherapy and Pharmacology. 83(4). 659–671. 17 indexed citations
9.
Tsuji, Takahiro, Hiroaki Ozasa, Wataru Aoki, et al.. (2018). Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model. Molecular Cancer Research. 17(1). 212–224. 41 indexed citations
10.
Yamashita‐Kashima, Yoriko, Mieko Yanagisawa, Keigo Yorozu, et al.. (2018). Preclinical study of antitumor activity of trastuzumab emtansine in HER2-positive biliary tract cancer.. Journal of Clinical Oncology. 36(4_suppl). 256–256. 1 indexed citations
11.
Suda, Kenichi, Leslie Rozeboom, Koh Furugaki, et al.. (2017). Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. BioMed Research International. 2017. 1–7. 12 indexed citations
12.
Yanagisawa, Mieko, Keigo Yorozu, Mitsue Kurasawa, et al.. (2017). Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model. International Journal of Oncology. 51(2). 425–434. 64 indexed citations
13.
Furugaki, Koh, Toshiki Iwai, Keigo Yorozu, et al.. (2015). Impact of bevacizumab in combination with erlotinib on EGFR‐mutated non–small cell lung cancer xenograft models with T790M mutation or MET amplification. International Journal of Cancer. 138(4). 1024–1032. 31 indexed citations
14.
Furugaki, Koh, Hideyuki Yasuno, Toshiki Iwai, et al.. (2014). Melting curve analysis for mutations of EGFR and KRAS.. PubMed. 34(2). 613–21. 9 indexed citations
15.
Furugaki, Koh, Toshiki Iwai, Yoichiro Moriya, Naoki Harada, & Kaori Fujimoto-Ouchi. (2013). Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells. Lung Cancer. 83(1). 44–50. 21 indexed citations
16.
Yamashita‐Kashima, Yoriko, Shigeyuki Iijima, Keigo Yorozu, et al.. (2011). Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models. Clinical Cancer Research. 17(15). 5060–5070. 150 indexed citations
17.
Furugaki, Koh, Yoichiro Moriya, Toshiki Iwai, et al.. (2011). Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292. Clinical & Experimental Metastasis. 28(7). 649–659. 39 indexed citations
18.
Furugaki, Koh, et al.. (2010). Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers. Oncology Letters. 1(2). 231–235. 11 indexed citations
19.
Yanagisawa, Mieko, Keigo Yorozu, Mitsue Kurasawa, et al.. (2010). Bevacizumab improves the delivery and efficacy of paclitaxel. Anti-Cancer Drugs. 21(7). 687–694. 57 indexed citations
20.
Orita, Tetsuro, Jun‐ichi Nezu, Takeshi Yoshino, et al.. (2008). Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications. 378(2). 279–284. 91 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kaori Fujimoto-Ouchi Breakdown of academic impact, for papers by Hoa Q. Trummell Breakdown of academic impact, for papers by A. Lambiase Breakdown of academic impact, for papers by Marissa S. Mattar Breakdown of academic impact, for papers by Muyun Peng Breakdown of academic impact, for papers by Kristin Gurtner Breakdown of academic impact, for papers by S. Ménard Breakdown of academic impact, for papers by H.A. Burris Breakdown of academic impact, for papers by Songbing Qin Breakdown of academic impact, for papers by Katharine D. Grugan
Rankless by CCL
2026